WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 16, 2005-- Preclinical Research Shows Definitive Biological Activity when CA4P or OXi4503 are Combined with Avastin. Principal Investigator Indicates that the Drug Combination Warrants Further Investigation as a Relevant Cancer Treatment . At the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics--OXiGENE, Inc. (NASDAQ: OXGN)(XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, today announced that new preclinical data for its vascular disrupting agents, Combretastatin A4P (CA4P) and OXi4503, were presented at the AACR/NCI/EORTC international cancer meeting in Philadelphia, PA. The research entitled, Dual Targeting of the Tumor Vasculature: Combining Avastin with CA4P or OXi4503, were presented by Dietmar Siemann, Ph.D., from the Department of Radiation Oncology, Shands Cancer Center, University of Florida, provided further validation of the therapeutic benefit in cancer of combining vascular disrupting agents and anti-angiogenic drugs. The data show that the combination of CA4P or OXi4503 with the anti-angiogenic drug, Avastin(R) (Bevacizumab), could offer a powerful and highly targeted treatment strategy for fighting solid tumors.
